1. Search Result
Search Result
Results for "

Potential difference

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Screening Libraries

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0234

    Prostenoglycine; TTPG; Tiase

    Others Endocrinology
    Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
    Stepronin
  • HY-129424

    KM-1146

    Others Inflammation/Immunology
    Mezolidon (KM-1146) is a compound with anti-ulcer activity, which exerts its anti-ulcer activity by enhancing the defense ability of gastric mucosa, especially by increasing and maintaining gastric mucosal blood flow and protecting gastric mucosal potential difference. Mezolidon can be used for the study of gastric mucosal protection .
    Mezolidon
  • HY-127040

    Histamine Receptor Inflammation/Immunology
    Talastine hydrochloride is an antihistamine with antiallergic activity. Talastine hydrochloride is used to relieve allergic symptoms. Talastine hydrochloride may cause adverse reactions such as rash, indicating differences in individual sensitivity. Talastine hydrochloride is considered a potential option for inhibiting allergic reactions .
    Talastine hydrochloride
  • HY-A0234R

    Others Endocrinology
    Stepronin (Standard) is the analytical standard of Stepronin. This product is intended for research and analytical applications. Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
    Stepronin (Standard)
  • HY-118839

    Endogenous Metabolite Infection
    Trans-Phenothrin is a synthetic pyrethroid with activity against adult fleas and ticks. Trans-Phenothrin has shown significant differences in biological activity between its different enantiomers in comparison with fenvalerate and d-trans-phenothrin. Trans-Phenothrin is used in agriculture for its potential insecticide activity against pests such as Plutella xylostella .
    trans-Phenothrin
  • HY-109743

    Others Neurological Disease
    BP14979 is a dopamine D3 receptor agonist with activity in the study of neurological diseases. BP14979 can be used to develop ligands with higher selectivity and affinity for D3 receptors. The structural characteristics of BP14979 make it potential in modulating the efficacy of D3 receptors. The design of BP14979 is based on the difference in efficacy with D3R selective antagonists, providing opportunities for optimizing new drug development .
    BP14979
  • HY-124317

    Others Others
    PF-06649283 is a drug with potential intracellular activity. The effects of PF-06649283 may be affected by factors such as cellular metabolism, protein-protein interactions, post-translational modifications, and asymmetric intracellular localization. The potency of PF-06649283 at the cellular level may show different activity compared to the recombinant enzyme, and this difference needs to be considered in the drug discovery process. Increased intracellular potency of PF-06649283 may be critical for the development of this drug as a probe or drug .
    PF-06649283
  • HY-123702

    Polo-like Kinase (PLK) Cancer
    CAP-53194 is a selective Plk1 inhibitor with potential anticancer activity. CAP-53194 was identified by a high-throughput virtual screening approach using molecular docking, showing 100-fold selectivity for Plk1 over Plk2-4 and other cell cycle kinases. CAP-53194 is able to effectively exploit subtle differences between the binding sites of Plk1 and other Ser/Thr kinases, thereby enhancing their inhibitory effects. CAP-53194 meets the Lipinski compound analog criteria and passes other ADMET filters, indicating good compound compatibility. CAP-53194 belongs to a new class of potential Plk1 inhibitors suitable for subsequent compound development and testing .
    CAP-53194
  • HY-158732

    Monoamine Oxidase Inflammation/Immunology
    MAO-B-IN-33 (compound C3) is a potent, reversible and selective monoamine oxidase-B (MAO-B) inhibitor with an IC50 of 0.021 μM and 26.805 μM for MAO-B and MAO-A, respectively. The selectivity of MAO-B-IN-33 is attributed to the steric clash arising from the residue differences between Phe208 (MAO-A) and Ile199 (MAO-B). MAO-B-IN-33 inhibits cerebral MAO-B activity and alleviates MPTP (HY-15608)-induced dopaminergic neuronal loss in the mouse. MAO-B-IN-33 has the potential for Parkinson's disease research .
    MAO-B-IN-33

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: